Revvity, Inc. (RVTY)

Market Cap	13.89B
Revenue (ttm)	2.72B
Net Income (ttm)	254.30M
Shares Out	121.70M
EPS (ttm)	2.06
PE Ratio	55.14
Forward PE	22.46
Dividend	$0.28 (0.25%)
Ex-Dividend Date	Jan 17, 2025

Volume	238,361
Open	111.38
Previous Close	111.34
Day's Range	110.74 - 114.13
52-Week Range	86.30 - 129.50
Beta	1.06
Analysts	Buy
Price Target	129.40 (+13.38%)
Earnings Date	Nov 4, 2024

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its pro...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,500
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2023, Revvity's revenue was $2.75 billion, a decrease of -16.95% compared to the previous year's $3.31 billion. Earnings were $693.09 million, an increase of 21.77%.

Analyst Forecast

According to 16 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $129.4, which is an increase of 13.38% from the latest price.

Price Target

$129.4

(13.38% upside)

Analyst Consensus: Buy